Disitamab ELISA试剂盒(靶标：)

Disitamab ELISA Kit

货号：RB9T37014623

在您使用本产品前请认真阅读说明书，这对您顺利完成实验很有帮助。

产品编码
RB9T37014623

中文名称
Disitamab ELISA试剂盒(靶标：)

英文名称
Disitamab ELISA Kit

应用
ELISA

登录号
P04626

检测方法
Colorimetric

灵敏度
0.156 μg/ml

检测范围
0.31-5 μg/mL

回收率
80-120%

样本类型
Plasma, Serum

检测类型

Quantitative

背景信息

Disitamab vedotin (Aidixi®) is an antibody-drug conjugate comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent monomethyl auristatin E. Disitamab vedotin is being developed by RemeGen for the treatment of solid tumours, including gastric cancer; Seagen has the right to develop disitamab vedotin globally outside of RemeGen's territory. In June 2021, disitamab vedotin received its first Biologics License Application (BLA) approval in China for the treatment of patients with HER2-overexpressing (defined as IHC2+ or 3+) locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two systemic chemotherapy regimens. Disitamab vedotin as monotherapy or combination therapy is also in clinical development for the treatment of other solid tumours globally, including urothelial cancer in China and the USA, and biliary tract cancer, non-small cell lung cancer and HER2-positive and HER2-low expressing breast cancer in China. This article summarizes the milestones in the development of disitamab vedotin leading to this first approval for locally advanced or metastatic gastric cancer.

别名

RC48-0, Disitamab Vedotin, 2185868-98-6

稳定性和储存

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

运输条件

2-8 ℃

For Research Use Only.